Published • loading... • Updated
Biosimilars Council and AAM endorse House bill to streamline biosimilar development
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biosimilars Council and AAM endorse House bill to streamline biosimilar development
WASHINGTON — The Biosimilars Council and the Association for Accessible Medicines applauded legislation, the Expedited Access to Biosimilars Act, introduced this week in the House of Representative by Nick Langworthy (R., N.Y.) and Kim Schrier, (D., Wash.), to codify the FDA's science-based approach to biosimilar review by limiting comparative efficacy studies.AAM and the Biosimilars Council have long advocated for a more efficient, science-base…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
